GlassScriptPhysician profile
Catherine Anne Obrien
NPI 1417994047
$2,006.64
in general payments reported to CMS, 2019-2025
30 companies · $465 in 2025
The $465 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $243 · 2020: $213 · 2021: $264 · 2022: $248 · 2023: $273 · 2024: $301 · 2025: $465.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $928 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $927.75 |
| Education | $111.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $268.29 | 2019-2025 | Vyloy, Padcev |
| Merck Sharp & Dohme LLC | $253.94 | 2019-2025 | Keytruda, Keytruda Qlex |
| Pfizer INC. | $238.17 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $156.48 | 2019-2025 | Opdivo |
| Novartis Pharmaceuticals Corporation | $148.18 | 2019-2025 | |
| Glaxosmithkline, LLC. | $119.04 | 2022-2025 | Ojjaara, Blenrep, Zejula |
| Janssen Biotech, INC. | $95.76 | 2019-2023 | Rybrevant |
| Kite Pharma, INC. | $81.83 | 2023-2024 | Yescarta |
| Gilead Sciences, INC. | $55.20 | 2021-2024 | |
| Emd Serono, INC. | $47.21 | 2019-2024 | |
| Daiichi Sankyo INC. | $43.24 | 2023-2024 | Vanflyta, Injectafer |
| Eisai INC. | $40.90 | 2021-2022 | |
| Stemline Therapeutics INC. | $40.31 | 2025 | Elzonris |
| Amgen INC. | $40.11 | 2020-2021 | |
| Abbvie INC. | $34.26 | 2024 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $33.00 | 2021-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $31.66 | 2022 | |
| Genentech USA, INC. | $28.70 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $28.01 | 2023 | |
| Organon LLC | $25.21 | 2022 | |
| Taiho Oncology, INC. | $24.55 | 2024 | |
| Myovant Sciences INC. | $23.93 | 2021 | |
| Genzyme Corporation | $23.32 | 2022 | |
| Springworks Therapeutics, INC. | $20.88 | 2025 | Ogsiveo |
| Sanofi-Aventis U.S. LLC | $20.82 | 2019 | |
| Aveo Pharmaceuticals, INC. | $20.00 | 2025 | |
| Servier Pharmaceuticals LLC | $19.88 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $16.23 | 2023 | Onivyde, Tazverik |
| Exelixis INC. | $14.66 | 2022 | |
| Jazz Pharmaceuticals INC. | $12.87 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Obrien listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.